肺癌诊断的进展：分子生物学对支气管镜诊断的贡献

东海 王(太和县人民医院，中国)
孟先 任(太和县人民医院，中国)
后洲 江(太和县人民医院，中国)
友飞 赵(太和县人民医院，中国)
冬 刘(太和县人民医院，中国)

摘要

近年来，基因组学、转录组学和蛋白质组学的重大进展改变了我们对肺癌发病机理的分子机制的理解，并正在彻底改变我们的诊断和治疗方法。虽然这些技术传统上被描述为对手术切除的肿瘤进行大体积活检，但重大的技术进步使它们可以应用于支气管镜下获得的较小样本，这通常是晚期肺癌唯一可用的样本。使用先进的分子技术进行组织学检查的手段包括：通过荧光原位杂交技术对非小细胞肺癌的早期诊断和筛查；通过新的免疫组织化学标记进行准确的组织学诊断以及靶向和常规化疗药物的预后和反应预测。分子生物学技术越来越多地应用于较小的活检标本，使其在晚期不可切除的非小细胞肺癌中的应用成为可能。　

关键词

肺癌；分子生物学；诊断；治疗　

参考

McWilliams A, Lam B, Sutedja T. Early proximal lung cancer diagnosis and treatment. Eur Respir J, 2009(33):656-665.

Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med,

(132):384-396.

Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol, 2010(41):20-25.

Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol, 2009(22):1032-1043.

Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009(373):1525-1531.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med, 2005(353):123-132.

Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009(361):958-967.

Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of nonsmall cell lung cancer using high-resolution melting analysis. Am J Clin Pathol, 2006(126):608-615.

Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol,

(16):538-548.

Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung ancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol, 2008(26):983-994.

Janne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res, 2006(12):751-758.

Reed E. ERCC1 and clinical resistance to platinum-based therapy.Clin Cancer Res, 2005(11):6100-6102.

Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis- directed individualized therapy in advanced nonsmall-cell lung cancer. J Clin Oncol, 2007(25):2741-2746.

DOI: http://dx.doi.org/10.26549/yzlcyxzz.v3i5.5247